DRNA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DRNA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Dicerna Pharmaceuticals's cost of goods sold for the three months ended in Sep. 2021 was $0.0 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Sep. 2021 was $0.0 Mil.
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Dicerna Pharmaceuticals's Gross Margin % for the three months ended in Sep. 2021 was 100%.
Cost of Goods Sold is also directly linked to Inventory Turnover.
The historical data trend for Dicerna Pharmaceuticals's Cost of Goods Sold can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dicerna Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | |||||||||||
Cost of Goods Sold | Get a 7-Day Free Trial | - | - | - | - | - |
Dicerna Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | |
Cost of Goods Sold | Get a 7-Day Free Trial | - | - | - | - | - |
Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.
Cost of Goods Sold for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dicerna Pharmaceuticals (NAS:DRNA) Cost of Goods Sold Explanation
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.
Dicerna Pharmaceuticals's Gross Margin % for the three months ended in Sep. 2021 is calculated as:
Gross Margin % | = | (Revenue | - | Cost of Goods Sold) | / | Revenue |
= | (62.954 | - | 0) | / | 62.954 | |
= | 100 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.
Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:
Dicerna Pharmaceuticals's Inventory Turnover for the three months ended in Sep. 2021 is calculated as:
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 0 | / | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.
Thank you for viewing the detailed overview of Dicerna Pharmaceuticals's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.
Bob D Brown | officer: See Remarks | 87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140 |
Shreeram Aradhye | officer: EVP & Chief Medical Officer | C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Marc D Kozin | director | |
Douglas Fambrough | director, officer: President and CEO | C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON MA 02421 |
James B Weissman | officer: Chief Operating Officer & EVP | C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421 |
Regina M. Paglia | officer: Chief Human Resources Officer | C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421 |
Robert D. Ciappenelli | officer: Chief Commercial Officer | DICERNA PHARMACEUTICALS, INC. 87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140 |
Adam Koppel | director | C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116 |
Anna Protopapas | director | MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Stephen K Doberstein | director | 129 ELSIE STREET, SAN FRANCISCO CA 94110 |
Patrick M. Gray | director | C/O CIVITAS SOLUTIONS, INC. 313 CONGRESS STREET, 6TH FLOOR BOSTON MA 02210 |
J Kevin Buchi | director | 41 MOORES ROAD, FRAZER PA 19355 |
Martin I Freed | director | 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140 |
Cynthia Smith | director | 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
Stephen J Hoffman | director | C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301 |
From GuruFocus
By Business Wire Business Wire • 08-09-2021
By PRNewswire PRNewswire • 11-22-2021
By Business Wire Business Wire • 12-25-2021
By GuruFocusNews GuruFocusNews • 11-18-2021
By PRNewswire PRNewswire • 12-14-2021
By Business Wire Business Wire • 09-28-2021
By Business Wire Business Wire • 09-02-2021
By PRNewswire PRNewswire • 11-20-2021
By GuruFocusNews GuruFocusNews • 11-18-2021
By Business Wire Business Wire • 09-22-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.